Matinas Biopharma Q4 2023 Earnings Report $0.56 +0.04 (+7.88%) As of 02:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Matinas Biopharma EPS ResultsActual EPS-$0.03Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMatinas Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMatinas Biopharma Announcement DetailsQuarterQ4 2023Date3/27/2024TimeQ4 2023 Earnings ReleaseConference Call ResourcesConference CallConference Call TranscriptMTNB Earnings History Remove Ads Matinas Biopharma Earnings HeadlinesMatinas BioPharma announces board chairman’s departureMarch 16, 2025 | investing.comMatinas BioPharma appoints Murphy, Neugeboren to board of directorsMarch 11, 2025 | markets.businessinsider.comIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”... “The future of AI”... And “a revolutionary leap forward.” Tech legend and angel investor Jeff Brown believes this AI is so powerful that it will kill ChatGPT… And make a lot of people rich in the process.April 1, 2025 | Brownstone Research (Ad)Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of DirectorsMarch 11, 2025 | finance.yahoo.comMatinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of DirectorsFebruary 13, 2025 | globenewswire.comMatinas BioPharma announces board member retirementFebruary 11, 2025 | msn.comSee More Matinas Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Matinas Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Matinas Biopharma and other key companies, straight to your email. Email Address About Matinas BiopharmaMatinas Biopharma (NYSE:MTNB) is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.View Matinas Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
